GlassScriptPhysician profile
William L Pearman
NPI 1659860765
$2,278.66
in general payments reported to CMS, 2019-2025
30 companies · $14.07 in 2025
The $14.07 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $329 · 2023: $1,736 · 2024: $200 · 2025: $14.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,602 · Education: $347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,602.47 |
| Education | $346.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $315.10 | 2022-2024 | Darzalex, Erleada, Tecvayli |
| Pfizer INC. | $216.47 | 2022-2024 | |
| Seagen INC. | $211.68 | 2022-2023 | Tukysa |
| Lilly USA, LLC | $179.41 | 2023 | Retevmo, Verzenio, Jaypirca |
| Astrazeneca Pharmaceuticals LP | $174.00 | 2023-2024 | Imfinzi, Lynparza, Enhertu |
| Merck Sharp & Dohme LLC | $144.76 | 2022-2023 | Keytruda, Lynparza |
| Eisai INC. | $130.21 | 2022-2023 | |
| Incyte Corporation | $118.59 | 2023 | Monjuvi, Jakafi |
| Celgene Corporation | $101.12 | 2022-2024 | Reblozyl |
| Genzyme Corporation | $98.96 | 2022-2023 | |
| Abbvie INC. | $66.93 | 2023 | |
| Servier Pharmaceuticals LLC | $64.49 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $60.50 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $53.73 | 2023 | Opdivo, Opdualag |
| Genmab U.S., INC. | $36.88 | 2023 | Tivdak |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $33.13 | 2022-2023 | Injectafer |
| Rigel Pharmaceuticals, INC. | $29.61 | 2022-2023 | Rezlidhia, Tavalisse |
| Kite Pharma, INC. | $29.54 | 2023 | Yescarta |
| Gilead Sciences, INC. | $22.85 | 2023 | Trodelvy |
| Apellis Pharmaceuticals, INC. | $22.69 | 2023 | Empaveli |
| Regeneron Healthcare Solutions, INC. | $20.84 | 2023 | Libtayo |
| Stemline Therapeutics INC. | $18.79 | 2023 | Elzonris |
| Springworks Therapeutics, INC. | $18.60 | 2024 | Ogsiveo |
| Amgen INC. | $17.41 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.19 | 2022 | |
| Mirati Therapeutics, INC. | $16.84 | 2023 | Krazati |
| Sobi, INC | $15.61 | 2023 | |
| Adaptive Biotechnologies Corporation | $14.62 | 2022 | |
| Terumo Medical Corporation | $14.07 | 2025 | Angio-Seal, Glidewire, Azur Cx Detachable |
| Bayer Healthcare Pharmaceuticals INC. | $14.04 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Pearman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.